Phase 2 Study of DPX-Survivac Combo Doses First Lymphoma Patient
News
A Phase 2 trial testing Immunovaccine‘s combination of DPX-Survivac with chemotherapy and an immune checkpoint inhibitor in diffuse large B-cell lymphoma (DLBCL) has dosed its first participant. The trial is supported by Merck ... Read more